CAR T cellshematological malignanciesreviewThe current standard of care in hematological malignancies has brought considerable clinical benefits to patients. However, important bottlenecks still limit optimal achievements following a current medical practice. The genetic complexity of the diseases and the hetero...
“Are They Ready Yet?”: release criteria for autologous CAR T cells Andrew P. Jallouk Olalekan Oluwole Bhagirathbhai Dholaria Editorial17 Jan 2025Bone Marrow Transplantation P: 1-2 Cancer cell reprogramming: turning the enemy into an ally ...
Herein, we present the design of light-switchable CAR (designated LiCAR) T cells that allow real-time phototunable activation of therapeutic T cells to precisely induce tumour cell killing. When coupled with imaging-guided, surgically removable upconversion nanoplates that have enhanced near-infrared-...
Lymphodepletion chemotherapy is usually required before CAR-T cell infusion to minimize the possibility of host immune system rejection of CAR-T cells, thus prolonging their persistence [27]. Recently, Mo et al. engineered an alloimmune defense receptor (ADR) that selectively targets 4-1BB, a c...
Research is ongoing with the goals of improving the safety profile, increasing the effectiveness, and expanding the applicability of CAR T-cell therapy to solid tumors.Keywords CAR-T; cancer; solid tumors; leukaemiaFull Text: PDF References 1. CAR T Cells: Engineering Immune Cells to Treat ...
T cells. NK cells and macrophages are the major players of innate immune cells in solid tumors [15]. NK cells share a similar cytotoxic function with CD8-positive cells by releasing perforin and granzyme. CAR-NK cells have antigen-independent and antigen-dependent tumor-killing capacities ...
The field has rapidly advanced from a promising form of immuno-oncology in preclinical models to the recent commercial approvals of chimeric antigen receptor (CAR) T cells to treat leukemia and lymphoma. This Review describes opportunities and challenges for entering mainstream oncology that presently ...
(CAR) (Humphries 2013). Adoptive T-cell therapy involves removing a patient's T cells, modifying themex vivo, and then reinfusing the modified cells back into the same patient (Figure 1). In addition to this so-called autologous approach, several companies worldwide are working on developing...
It forms part of a new line of immune-boosting CAR T cell therapy treatments, which take a patient's own immune cells and modify them in a lab before reintroducing them into the body. Gregor McNie, Cancer Research UK's head of external relations in Scotland, called the rejection "disappoi...
CD19 CAR T-cells are a type of immunotherapy in which a patient's T cells are extracted from their blood and modified in a lab to recognize CD19, a target on the surface of leukemia cells. The engineered T cells are then infused back into the patient where they multiply and hunt down...